Skip to Content
Merck
CN

775118

Borane dimethyl sulfide complex solution

greener alternative

1.0 M in 2-methyltetrahydrofuran

Synonym(s):

BMS, Trihydro[thiobis[methane]]boron

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Linear Formula:
(CH3)2S · BH3
CAS Number:
13292-87-0
Molecular Weight:
75.97
UNSPSC Code:
12352112
NACRES:
NA.22
PubChem Substance ID:
329767736
MDL number:
MFCD00013189
Beilstein/REAXYS Number:
3663489

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Borane dimethyl sulfide complex solution, 1.0 M in 2-methyltetrahydrofuran

InChI

1S/C2H6S.BH3/c1-3-2;/h1-2H3;1H3

SMILES string

B.CSC

InChI key

RMHDLBZYPISZOI-UHFFFAOYSA-N

form

liquid

reaction suitability

reagent type: reductant

greener alternative product characteristics

Safer Solvents and Auxiliaries
Use of Renewable Feedstocks
Inherently Safer Chemistry for Accident Prevention
Learn more about the Principles of Green Chemistry.

sustainability

Greener Alternative Product

concentration

1.0 M in 2-methyltetrahydrofuran

density

0.844 g/mL at 25 °C

functional group

thioether

greener alternative category

, Aligned

storage temp.

2-8°C

Quality Level

100

Looking for similar products? Visit Product Comparison Guide

Related Categories

Application

2-Methyltetrahydrofuran (2-MeTHF): A Biomass-Derived Solvent with Broad Application in Organic Chemistry
Commonly used in hydroboration of olefins and as a reductant of carbonyls. 2-Me-THF has shown potential as an environmentally friendly solvent compared to commonly used solvents; e.g. dichloromethane and THF.
For an alternative to Tetrahydrofuran and Dichloromethane, please see: An alternative to Tetrahydrofuran and Dichloromethane
Reactant used as a regioselective reducing agent

Reactant involved in:
  • Hydroboration / oxidation
Synthesis of cage compounds

General description

We are committed to bringing you Greener Alternative Products, which adhere to one or more of The 12 Principles of Greener Chemistry. This product, 1.0 M in 2-methyltetrahydrofuran aligns with "Safer Solvents and Auxiliaries", "Use of Renewable Feedstocks" and "Inherently Safer Chemistry for Accident Prevention". Find details here.

Packaging

The 25 mL Sure/Seal™ bottle is recommended as a single-use bottle. Repeated punctures will likely result in decreased performance of product.

Legal Information

Sure/Seal is a trademark of Sigma-Aldrich Co. LLC

signalword

Danger

Hazard Classifications

Acute Tox. 4 Oral - Eye Dam. 1 - Flam. Liq. 2 - Repr. 1B - Skin Irrit. 2 - Water-react 1

supp_hazards

EUH019

Storage Class

4.3 - Hazardous materials which set free flammable gases upon contact with water

wgk

WGK 2

flash_point_f

9.3 °F

flash_point_c

-12.6 °C

Regulatory Information

危险化学品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
SHBR0860
SHBL6342
SHBK2868
SHBJ1749
SHBG1668V

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Isidoro González-Álvaro et al.
Rheumatology (Oxford, England), 54(7), 1200-1209 (2014-12-21)
The aim of this study was to establish guidelines for the optimization of biologic therapies for health professionals involved in the management of patients with RA, AS and PsA. Recommendations were established via consensus by a panel of experts in
Veena K Ranganath et al.
Arthritis care & research, 67(7), 929-939 (2015-01-13)
To evaluate the effect of sustained American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) Boolean remission on residual joint inflammation assessed by magnetic resonance imaging (MRI) and to secondarily evaluate other clinical definitions of remission, within an early seropositive
Saskia Ditisheim et al.
Inflammatory bowel diseases, 21(11), 2598-2604 (2015-08-06)
Inflammatory bowel diseases (IBD) are systemic conditions that commonly display extraintestinal manifestations. Inflammatory articular disease (IAD: axial or peripheral) is the most common extraintestinal manifestation. The aim of this study was to evaluate the prevalence and the clinical characteristics associated
Marieke M ter Wee et al.
Annals of the rheumatic diseases, 74(6), 1233-1240 (2014-05-14)
Recently, we documented the likely non-inferiority of Combinatietherapie Bij Reumatoïde Artritis (COBRA)-light therapy (methotrexate increased to 25 mg/week with initial prednisolone 30 mg/day) compared with the original COBRA therapy (methotrexate 7.5 mg/week, sulfasalazine 2 g/day, with initial prednisolone 60 mg/day) after 26 weeks in patients with
Pei-Chun Chen et al.
PloS one, 10(4), e0125257-e0125257 (2015-04-30)
Data on the use of oral anticoagulation (OAC) and antiplatelet therapy and the risk of bleeding and stroke amongst Asian patients with atrial fibrillation (AF) are limited. We investigated the risks of bleeding and stroke with use of oral anticoagulation
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service